3 enrolling by invitation. 3 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Enrolling by invitation 3 |
| Phase 2 | 1 | Enrolling by invitation 1 |
Follow Dyslipidemias: new trials by email Literature Review of Dyslipidemias trials Research Report on Dyslipidemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH lerodalcibep 300 mg Monthly SC - Familial Hypercholesterolemia - Heterozygous | Phase 3 | Enrolling by invitation | LIB Therapeutics LLC | 150 | 2026-07-20 | 2026-07-28 |
| Study on the Sex-specific, Lipid- and Lipoprotein-lowering Effects of Berberine Berberine, Placebo - Hyperlipidemia | Phase 2 / Phase 3 | Enrolling by invitation | The University of Hong Kong | 100 | 2024-08-01 | 2025-01-20 |
| Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction lerodalcibep - Cardiovascular Disease With Mention of Arteriosclerosis, Elevated Cholesterol | Phase 3 | Enrolling by invitation | LIB Therapeutics LLC | 2000 | 2020-12-03 | 2024-10-22 |
Hypercholesterolemia (2) · Hyperlipidemias (1) · Hyperlipoproteinemia Type II (1)
Lipid Metabolism Disorders (3) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Hyperlipidemias (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Genetic Diseases, Inborn (1) · Hyperlipoproteinemias (1) · Lipid Metabolism, Inborn Errors (1) · Metabolism, Inborn Errors (1)
Berberine (1)
LIB Therapeutics LLC (2) · The University of Hong Kong (1)
Israel (2) · Norway (2) · South Africa (2) · Turkey (Türkiye) (2) · United States (2) · Hong Kong (1) · India (1) · New Zealand (1)
David Kallend, MB BCh (1) · David Kallend, MB BS (1) · Jie Zhao, Dr (1)
2025 (1)